Polycystic Ovary Syndrome Renamed to Reflect Metabolic, Hormonal Complexity

A condition that affects somewhere between one in ten and one in thirteen women of reproductive age has just been given a new name. The change, announced this week in The Lancet by an international consortium of doctors and researchers, reflects something that has been quietly frustrating patients and fragmenting their care for decades: the old name was wrong.

For generations, millions of women experiencing irregular periods, pelvic pain, excess body hair, and acne have been told they have polycystic ovary syndrome, or PCOS. The name itself points to the ovaries—to cysts, to a reproductive problem. But here is the catch: most of these women do not actually have ovarian cysts. What they do have is a widespread disruption in how their bodies handle hormones and metabolism, a systemic disorder that touches far more than the reproductive system. The new name, metabolic polycystic ovarian syndrome, or SOMP, attempts to capture that reality.

The renaming process involved 56 organizations and thousands of patient and clinician surveys conducted over several years. The consortium's members wrote that the old name had actively harmed patients—delaying diagnosis, fragmenting care across different medical specialties, and creating stigma. It had also constrained research and policy development. When a condition is understood to affect a single organ, the entire apparatus of medicine—funding streams, educational curricula, clinical guidelines—gets locked into that narrow frame. In this case, the frame was wrong.

Consider what happens in medical school. Students learn about PCOS almost exclusively in gynecology courses, even though it is fundamentally an endocrine disorder affecting multiple body systems. Beyond the reproductive symptoms, the condition can trigger changes in hair and skin and carries elevated risk for obesity, type 2 diabetes, cardiovascular disease, and sleep apnea. Yet gynecologists and reproductive endocrinologists who treat these patients often do not refer them for screening of these other conditions, or even warn them that their risk is higher. The disease has been put in the wrong box, as Helena Teede, an endocrinologist and women's health professor at Monash University in Australia and lead author of the consortium's paper, put it. Everything follows from that initial misplacement.

The practical consequences ripple outward. When researchers like Melanie Cree, a pediatric endocrinology professor at the University of Colorado Anschutz, apply for grants through the National Institutes of Health to study the condition, their applications typically land in the institute focused on reproductive health—which has a relatively small budget. With the new name, research on SOMP could potentially compete for funding through institutes covering diabetes and heart disease, where the money is larger. Other countries' health agencies and nonprofit research funders could similarly expand their support.

For patients themselves, the immediate effects may be tangible. The new framing could prompt physicians to order more screening for metabolic and cardiovascular problems. Currently, many patients are prescribed birth control for symptom management if they are not trying to conceive—and while this can be quite effective, it does not address the full scope of the disorder. A broader understanding of what SOMP actually is might open the door to additional treatments. But much more research is needed. Because funding has been so limited, patients have often been treated off-label with drugs approved for other conditions.

Experts emphasize that patients with SOMP should be monitored closely for insulin resistance and cardiovascular risk factors like high cholesterol, and should receive counseling on nutrition and lifestyle changes. There is also the matter of endometrial cancer risk, which is elevated and which women need to know about. Basma Faris, an associate professor of obstetrics, gynecology, and reproductive sciences at the Icahn School of Medicine at Mount Sinai, said she hoped the name change would reorient thinking toward viewing this as a long-term chronic condition rather than merely a period problem. Over the next three years, the consortium plans an international campaign to communicate and explain the shift. The real test will be whether the medical system actually reorganizes itself around this new understanding.